Sam Brusco, Associate Editor03.22.22
Bone and soft tissue regeneration and infection management firm Biocomposites began a multiyear agreement with Zimmer Biomet to exclusively distribute Biocomposites’ genex bone graft substitute with new mixing system and delivery options in the U.S.
genex is a biphasic calcium sulfate and β-tricalcium phosphate composite formulated to balance osteoconductive scaffold strength and persistence for ideal bone architecture remodeling. As part of the agreement, genex was upgraded to include a new closed-mixing system to shorten prep time and lengthen working time. Surgeons can also inject, mold, or prepare beads with their chosen technique thanks to more comprehensive delivery options.
It also features negative charged surface chemistry that has shown favorable osteogenic bone growth response. genex’s recrystallization and purification production methods remove nonabsorbing compounds like hydroxyapatite to ensure complete absorption and remodeling within a year.
Michael Harris, CEO of Biocomposites, told the press, “I am delighted we are partnering with Zimmer Biomet to deliver our new genex Bone Graft Substitute product to the U.S. market. genex is already used and valued by surgeons in over 30 countries, including the U.S., undertaking 15,000 cases each year. The upgraded offering which we are providing to Zimmer Biomet will further benefit many more physicians and patients across the U.S.”
Brian Hatcher, president of Zimmer Biomet’s CMFT, Foot & Ankle and Trauma added, “We are excited to partner with Biocomposites to bring the new genex Bone Graft Substitute kits to surgeons as we continue to advance our mission to alleviate pain and improve the quality of life for people around the world.”
genex is a biphasic calcium sulfate and β-tricalcium phosphate composite formulated to balance osteoconductive scaffold strength and persistence for ideal bone architecture remodeling. As part of the agreement, genex was upgraded to include a new closed-mixing system to shorten prep time and lengthen working time. Surgeons can also inject, mold, or prepare beads with their chosen technique thanks to more comprehensive delivery options.
It also features negative charged surface chemistry that has shown favorable osteogenic bone growth response. genex’s recrystallization and purification production methods remove nonabsorbing compounds like hydroxyapatite to ensure complete absorption and remodeling within a year.
Michael Harris, CEO of Biocomposites, told the press, “I am delighted we are partnering with Zimmer Biomet to deliver our new genex Bone Graft Substitute product to the U.S. market. genex is already used and valued by surgeons in over 30 countries, including the U.S., undertaking 15,000 cases each year. The upgraded offering which we are providing to Zimmer Biomet will further benefit many more physicians and patients across the U.S.”
Brian Hatcher, president of Zimmer Biomet’s CMFT, Foot & Ankle and Trauma added, “We are excited to partner with Biocomposites to bring the new genex Bone Graft Substitute kits to surgeons as we continue to advance our mission to alleviate pain and improve the quality of life for people around the world.”